View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 14, 2022

Innoskel enrols first patient to study collagen disorders in children

The company will leverage the study results to inform the design of its planned interventional clinical trial for INS-101.

Innoskel has enrolled the first patient in the global, observational ROCKET study of its preclinical gene therapy candidate INS-101 to analyse the course of type II collagen disorders in children living with short stature.

The multi-centre study is enrolling children of the age zero to 12 years, with a confirmed diagnosis of a type II collagen disorder.

The company plans to collect data prospectively on relevant endpoints that range from clinical manifestations, including physical and respiratory function, growth, to laboratory values and quality of life reported by the patient.

Innoskel CEO and founder Elvire Gouze said: “The significant lack of data available on type II collagen disorders highlights the important need to collect this type of data to not only inform clinical development but also to help with clinical care including establishing best practices.

“We look forward to partnering with our sites to execute this study and increase our collective knowledge so that we may efficiently advance INS-101 with a goal of delivering a new and much needed treatment for these children.”

By leveraging the ROCKET study results, the company will inform the design of its planned interventional clinical trial for INS-101.

This therapy is being developed to treat patients with type II collagen disorders.

At present, INS-101 is being investigated for restoring normal cartilage growth in bone growth plates and prevention of the skeletal deformities that lead to severe clinical complications in collagen disorders.

These complications include hip deformity, early onset osteoarthritis, cervical instability, vision and breathing difficulties.

Innoskel chief patient access officer Samantha Parker said: “With INS-101, we have the potential to fundamentally change the treatment paradigm for children with type II collagen disorders and provide them with a meaningful difference in their quality of life.

“The findings from this observational study will help us accelerate the development of INS-101 and bring this transformative therapy to individuals who have been waiting for new options.”

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena